Live Breaking News & Updates on Regeneron Velocimmune

Stay updated with breaking news from Regeneron velocimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

31.05.2024 - Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, . ....

France General , United States , Georged Yancopoulos , Regeneron Velocimmune , Regeneron Velocimmunetechnology , Regeneron Genetics Center , Drug Administration , Regeneron Pharmaceuticals Inc , European Commission Of Dupixent , European Commission , European Union , Exchange Commission , Dupilumab Development Program , Clinical Research Program , Us Department Of Justice , European Medicines Agency , Human Use , Respiratory Questionnaire , Biologics License Application , Chief Scientific Officer George , Nasal Polyposis , Forward Looking Statements , Regeneron Pharmaceuticals , Medicinal Products , Product Candidates ,

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved. ....

France General , United States , Georged Yancopoulos , Hannah Kwagh , Timothy Gilbert , Regeneron Velocimmune , Nathalie Pham , Sandrine Guendoul , Evan Berland , Felix Lauscher , Arnaud Delepine , Thomas Kudsk Larsen , Tarik Elgoutni , Corentine Driancourt , Vesna Tosic , Clinical Research Program , Us Department Of Justice , European Commission , Exchange Commission , European Union , Dupilumab Development Program , European Commission Of Dupixent , Regeneron Genetics Center , Globenewswire Inc , Drug Administration , Regeneron Pharmaceuticals Inc ,

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has extended by three months the target action date of. ....

United States , France General , Nathalie Pham , Sandrine Guendoul , Evan Berland , Hannah Kwagh , Timothy Gilbert , Georged Yancopoulos , Regeneron Velocimmune , Arnaud Delepine , Tarik Elgoutni , Vesna Tosic , Corentine Driancourt , Eva Schaefer Jansen , Felix Lauscher , Regeneron Genetics Center , Committee For Medicinal Products Human Use , Regeneron Pharmaceuticals Inc , Drug Administration , Dupilumab Development Program , Exchange Commission , European Union , European Medicines Agency , Clinical Research Program , Us Department Of Justice , Biologics License Application ,

Update On FDA Priority Review Of Dupixent® (Dupilumab) For The Treatment Of COPD Patients With Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food a ....

United States , France General , Regeneron Velocimmune , Georged Yancopoulos , Clinical Research Program , Us Department Of Justice , Exchange Commission , Dupilumab Development Program , Committee For Medicinal Products Human Use , Regeneron Pharmaceuticals Inc , Drug Administration , European Union , Regeneron Genetics Center , European Medicines Agency , Biologics License Application , Medicinal Products , Human Use , Research Program , Chief Scientific Officer George , Nasal Polyposis , Prescribing Information , Forward Looking Statements , Digital Media , Regeneron Pharmaceuticals , Product Candidates ,

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) ...

Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy ....

United States , Regeneron Velocimmune , Vesna Tosic , Taylor Skott , Georged Yancopoulos , Neilh Segal , American Society Of Clinical Oncology , Regeneron Genetics Center , Us Department Of Justice , Exchange Commission , European Union , Drug Administration , Velocimmune Technology , Regeneron Pharmaceuticals , Regeneron Pharmaceuticals Inc , American Society , Clinical Oncology , Medical Oncologist , Research Director , Gastrointestinal Oncology , Memorial Sloan Kettering Cancer Center , Israel Lowy , Senior Vice President , Nonproprietary Naming , Biological Products Guidance , Prescribing Information ,